Insu Therapeutics wins US patent allowance for buccal semaglutide tablet
The layered InsuTab and BuccaGLP tablets stick to the inner cheek and bypass gastrointestinal absorption, with Hydreight holding US distribution rights.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 10 10:18 ETSource: Trend Hunter
The wire
- 01Insu Therapeutics received a US patent allowance covering its cheek-adhering delivery system for insulin (InsuTab) and semaglutide (BuccaGLP), following laboratory, cell-culture and animal work at the University of British Columbia.
- 02A non-injected incretin route that avoids gastrointestinal absorption and dosing-related fasting rules would change how clinics and pharmacies handle semaglutide supply if it reaches market.
- 03Both formulations are unapproved and have not been tested in humans; the company says further testing is needed to establish safety and effectiveness.
From the source
Read at trendhunter.comNeedle-Free Peptide Therapies: Insu Develops Cheek-Adhering Insulin and GLP-1 Treatments
Insu Therapeutics is advancing needle-free peptide therapies through its investigational InsuTab and BuccaGLP formulations, designed to deliver insulin and semaglutide without injections . The technology uses layered tablets that attach to the inner cheek, releasing medication toward surrounding tissue for absorption. Unlike swallowed treatments, the approach bypasses gastrointestinal absorption a
